Dr Glenn Begley

Since 2016 Dr Begley has been Chief Scientific Officer (CSO) at Akriveia Therapeutics. He advises several biotechnology companies and serves on the Scientific Advisory Board for the Cancer Science Institute of Singapore. Prior to Akriveia, for three years, he served as CSO at TetraLogic Pharmaceuticals, based in Malvern, PA. From 2002-2012, he was Vice-President and Global Head of Hematology/Oncology Research at Amgen, responsible for building, directing and integrating Amgen's five research sites. During this time he became interested in the issue of research integrity and scientific reproducibilty. Before joining Amgen he had over 20 years of clinical experience in medical oncology and hematology. His personal research has focused on regulation of hematopoietic cells and translational clinical trials.  His early studies first described human G-CSF, and in later clinical studies, he first demonstrated that G-CSF-"mobilized" blood stem cells hastened hematopoietic recovery compared with bone marrow transplantation.  This finding revolutionized the approach to clinical hematopoietic cell transplantation. He is Board Certified in Australia as a Medical Oncologist and Hematologist, has a PhD in cellular and molecular biology, and has received numerous honours and awards, including being elected as the first Foreign Fellow to the American Society of Clincical Investigation in 2000, to the Assocication of American Physicians in 2008, and to the Research "Hall of Fame" at his alma mater, the Royal Melbourne Hospital in 2014.

Professor Jonathan Cebon

Professor Cebon is the Medical Director of Cancer Services at the Olivia Newton John Cancer & Wellness Centre (ONJCWC) at Austin Health in Heidelberg, Victoria and the Director of the Ludwig Institute for Cancer Research.  A key focus of his research over the past 20 years has been the investigation of the power of the immune system to treat cancer. His clinical area of interest is the immune therapy of cancer and developmental therapeutics particularly for the treatment of melanoma. He holds professorial appointments at both Melbourne and La Trobe Universities and is a Fellow of the Royal Australasian College of Physicians. He is a lead investigator in the Victorian Cancer Agency funded Melbourne Melanoma Project. He serves on the Cancer Council of Victoria and is a member of the Consultative Council of the Victorian Cancer Agency. He is a member of Cancer Trials Australia, is a past chair of the grant Review Committee of Melanoma Research Alliance and serves on the Scientific Committees of the Cancer Vaccine Collaborative (CVC) and Cancer Research Institute (CRI), both organizations that play a major international role supporting basic, translational & clinical research into the immune therapy of cancer.

Dr Philippe Danjou

Dr Danjou is a Clinical Pharmacologist from Paris University. He trained at the Pitié-Salpétriêre Hospital and received his Medical Degree in 1984 which he followed with a PhD in human biology in 1990. After doing Post-Doctoral studies in anxiety at the New York Psychiatric Institute, and a short university career in France, he spent 20 years in the Pharmaceutical Industry where he was involved in the early development of compounds that were successfully registered such as Zolpidem (Synthelabo), Zaleplon and Venlafaxine (Wyeth). As Head of Clinical Pharmacology at Sanofi, Dr Danjou gained experience in Clinical Psychiatry and Human Pharmacodynamics. He also held a translational medicine role with Merck Sharp & Dohme at Terlings Park. In 2011 he joined the French CNS specialized CRO, Forenap, as Chief Scientific Officer. In addition to Bionomics, he is member of the scientific advisory boards of Enkam Pharmaceuticals A/S in Denmark and  Manros Therapeutics in France. Dr Danjou has initiated the International Pre-competitive Pharmaco-EEG Consortium (IPPEC) on the use of EEG as a translational biomarker and as coordinator, has submitted a EU FR7 large frame project on schizophrenia (Stigma®). In parallel Dr Danjou has recently completed two years of training and working on Pain Disorders at a Paris Hospital.

Dr Jayesh Desai

Dr Jayesh Desai practices as a Medical Oncologist at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre in Melbourne, and Senior Clinic Research Fellow within the Ludwig Colon Cancer Initiative program at the Ludwig Institute for Cancer Research in Parkville. He also serves as an Associate Director for Cancer Trials Australia (CTA) and Chairs the CTA Phase I Drug Development Group, and is Chair of the Australasian Sarcoma Study Group. Dr Desai completed his Medical Oncology training in Melbourne in 2002, before spending three years as a Translational Research Fellow at the Dana-Farber Cancer Institute/Harvard Medical School in Boston, USA. His clinical and research interests focus on rationally developing new anticancer therapeutics, and in exploring predictive markers of response to these agents. He has been Principal Investigator for more than a dozen first-in-human Phase 1 oncology trials, from small academically-focused groups and biotechs to large pharmaceutical company-sponsored trials. He has been closely involved in the development of Bionomics' Vascular Disrupting Agent, BNC105, as a Principal Investigator for that compound's first-in-human trial. 

Professor Paul Fitzgerald

Professor Fitzgerald is Professor of Psychiatry, Deputy Director and Consultant Psychiatrist at Alfred Psychiatry Research Centre, a joint research centre of Monash University and the Alfred Hospital in Melbourne. He is a qualified psychiatrist, has a Masters of Psychological Medicine and research PhD. He runs a substantive research program utilising brain stimulation and neuroimaging techniques including transcranial magnetic stimulation, functional and structural MRI, EEG and new infrared spectroscopy. The program has focussed on the conduct of investigative studies of brain function /dysfunction as well as the conduct of a variety of novel clinical trials in mood, anxiety, psychotic and Developmental Disorders. He has published over 90 papers and received grant funding from the NHMRC and a number of US based organisations including a NHMRC Practitioner Fellowship. He is on a variety of local and international committees including the scientific and review committees of Neuroscience Victoria.

Dr Richard Hargreaves

Dr Hargreaves has broad drug discovery, development and registration experience as a senior executive in pharmaceutical R&D. As VP Worldwide Discovery Head for neuroscience in Merck Research Laboratories he had overall responsibility for strategic and scientific direction including external scientific affairs, licensing and academic collaborations for the neuroscience drug discovery pipeline. Dr Hargreaves led programs that advanced new drug candidates to the clinic for Alzheimer’s disease, cognition, schizophrenia, migraine headache, pain and circadian disorders. In addition he was a core member of the global scientific strategy team that prioritized programs and investments across all therapeutic areas in the MRL discovery and development portfolio. While at Merck, he also led the discovery teams that contributed to the development and registration of MAXALT® (rizatriptan) for migraine, EMEND® (aprepitant) and IVEMEND® (fosaprepitant) for chemotherapy-induced nausea and vomiting, and suvorexant for insomnia. Dr Hargreaves has published extensively in peer-reviewed scientific journals on neuroscience drug discovery, translational biomarkers and the use of biomedical imaging in drug discovery and development. He received the Gary Neil Award for "Innovation in Drug Development" by the American Society of Clinical Pharmacology and Therapeutics for his work on imaging in drug discovery and development and the first Sir James Black Award for Drug Discovery by the British Pharmacological Society.

Dr Tim Harris

Dr Harris is a science and business leader with nearly 40 years of experience guiding and leading laboratory work and scientists in a range of molecular research areas.  He is a molecular biologist and biochemist, and is currently a Venture Partner with SV Life Sciences.  He was until March 2016, the Senior Vice President (SVP) of Precision Medicine at Biogen.  Before that he was SVP of Translational Medicine at Biogen Idec.  Until 2011, he was the Chief Technology Officer (CTO) and Director of the Advanced Technology Program (ATP) at SAIC-Frederick, Inc. in Maryland which operates the National Cancer Institute's Leading centre for cancer and AIDS research (now Frederick National Laboratory operated by Leidos Inc.).  He has served as President and Chief Executive Officer (CEO) of Novasite Pharmaceuticals, and he founded SGX Pharmaceuticals in 1999 (formerly Structural Genomix), where he built the company to more than 130 employees, raised US$85M in capital, and generated more than US$20M in revenue during six years as CEO before it was sold to Eli Lilly.  Before founding SGX, Dr Harris was SVP, Research and Development at Sequana/Axys.  He began his scientific career working on animal viruses such as foot & mouth disease and was one of the first molecular biologists (1981) at Celltech (now UCB Pharma) in the United Kingdom. He subsequently spent five years at Glaxo Group Research as Director of Biotechnology from 1989 to 1993.  He is currently on the Board of Directors of Opgen (Nasdaq:OPGN) and is an observer on the Board of SMS-IC in Scotland.  

Dr Ann Hayes

Dr Hayes worked for 22 years for GlaxoWellcome, initially in research, with particular expertise in the areas of CNS and pain. Before the GSK merger, she was a Director in Drug Discovery, and was involved in determining long-term discovery strategy, portfolio management and discovery project management. Dr Hayes left GSK in 2001 and set up a business as an independent pharmaceutical consultant. In this capacity she has co-founded three companies, Ionix Pharmaceuticals which has been bought by Vernalis, Therasci which has been bought by CeNeS, and Theradeas. Dr Hayes is a non-executive director for Curidium plc and Plethora Solutions plc, and a member of the advisory boards for CeNeS and Lectus. She has also held non-executive director positions at Therasci, Ionix and Sirus (which was sold to Arakis). She currently consults regularly for CeNes and Shire, as well as doing ad hoc consulting for a number of small companies and VCs.

Dr José Iglesias

Dr Iglesias is the Vice President, Medical & Clincial Affairs at Apobiologix, Canada. Prior to this Dr Iglesias held the position of Chief Medical Officer (CMO) at Biothera and previous to that,  CMO at Bionomics from November 2012 to October 2015, where he was responsible for clinical development. Dr Iglesias has over 25 year's global experience in the biopharmaceutical industry. Before joining Bionomics, he spent six year's at Celgene and previous roles including CMO and VP of Global Clinical Development and Medical Affairs at Abraxis. Previously, Dr Iglesias worked in several positions at US pharmaceutical giant Eli Lilly over ten years, including his appointment as Oncology Medical Advisor for Australia and the Asia Pacific region between 2002 and 2004. A graduate from the Montevideo School of Medicine, Dr Iglesias has been published more than 60 times and is an active member of ASCO, AACR and ESMO.

Dr Fiona McLaughlin

Dr Fiona McLaughlin is the Head of Research and Development for the Heidelberg based oncology biotechnology company Elara Pharmaceuticals GmbH, responsible for progression of the drug development pipeline and licensing/collaboration activities. Prior to joining Elara, Dr McLaughlin was Director of Research and a member of the Senior Management Team at the UK based Antisoma Research Ltd from 2007-2010. Following Antisoma's acquisition of Boston-based Xanthus Pharmaceuticals Inc, she became VP Translational Research for the expanded company and built up an innovative portfolio of in-licensed early stage oncology assets. Prior to joining Antisoma, she has held the posts of Oncology Development Specialist and Head of Pre-Clinical development for the specialty pharmaceuticals company BTG in London, combining virtual drug development and in-licensing to expand and progress the drug development portfolio. From 2001-2004 Dr McLaughlin was Head of Biology for the Oxford based oncology company Prolifix Ltd which was later acquired by Topotarget A/S. Throughout this time she was primarily responsible for the research and non-clinical development activities that led to the clinical development of the HDAC inhibitor Belinostat. Dr McLaughlin gained her PhD from the Haematology Department at Cambridge University and carried out post-doctoral research at GlaxoSmithKline in the UK, where she subsequently held several research posts in vascular diseases, inflammation and steroid induced osteoporosis. In addition to her current post at Elara Pharmaceuticals, Dr McLaughlin is also an independent consultant to the pharmaceutical industry and is a fully elected Fellow of the Society of Biology.

Dr Jens Mikkelsen

Dr Mikkelsen is a translational neuroscientist.  He received his Medical Degree in 1986 from the University of Copehagen and after post-doctoral training in Denmark, UK and USA, he established a neuroscience research laboratory at the University of Copenhagen studying the circadian timing system. 

Since 1995, he spend 16 years in the pharmacrutical industry and key positions include Head of Neurobiology, H.Lundbeck, Director of Pharmacology, Zealand Pharma, CSO/CEO, Azign Bioscience, and Head of Translational Neuroscience, NeuroSearch. In these roled Dr Mikkelsen has been instrumental in target selection and target validation, and bringing early stage products to clinical testing. Examples include drugs for obesity, diabetes, depression, Alzheimer's disease, dyskinesia, and schizophrenia, some of which have been successful in late clinical trials entered into NDA. 

Dr Mikkelsen has also worked as group leader of the translational neuropharmacology group at the Univerity Hospital in Copenhagen, aimed at understanding the mechanism of action of CNS drugs, with special attention on cognitive enhancers. Dr Mikkelsen has published more than 250 original papers in the fields of neuroscience and pharmacology, and has been the inventor of a number of patents. 

Professor Danny Rischin

Professor Danny Rishcin is the Director of the Division of Cancer Medicine and Head of the Department of Medical Oncology at Peter Mac and a consultant Medical Oncologist at the Mercy Hospital for Women.  He holds an academic appointment as Professor of Medicine at The University of Melbourne and in 2011 was appointed an Associate Editor of the Journal of Clinical Oncology.  Professor Rischin graduated from Monash University and completed his interanl medicine and medical oncology training in Melbourne and Toronto.  He was Chair of the ANZGOG RAC from 2002 till 2011 and has been an executive member of the ANZGOG since its inception. 

Professor Paul Rolan

Professor Rolan is a clinical pharmacologist (MBBS MD FRACP), pharmaceutical physician (FFPM (UK)) and pain physician (FFPMANZCA).  His career has been split between the pharmaceutical industry, mainly in the UK, and academic and clinical practice in Australia and the UK. 

In drug development, his experience is mainly in exploratory development, having been prinicpal investigator in over 700 clinical studies of which more than 70 were first in-man, including Bionomics' BNC210. 

Paul was Professor of Clinical Pharmacology at the University of Adelaide from 2005-2014 and Head of the School of Medical Sciences in 2014.  After another stint in industry, hense returned to the University of Adelaide in late 2016 as Director of Innovation for the Faculty of Health Sciences. 

Paul continues in clincial practice in pain management. 

Dr Fiona Thomson

Dr Thomson is the Director of the Translational Pharmacology Laboratory within the Experimental Cancer Medicine Centre (ECMC), Glasgow, UK. Her group's research aims to leverage new discoveries in cancer sciences to improve the treatment of patients. The Translational Pharmacology Laboratory applies state-of-the-art technologies to discover and develop novel biomarkers and to aid early cancer diagnosis, cancer prognosis and to support the development of novel cancer therapies through phase I/II clinical trials. Prior to joining the University of Glasgow, Fiona spent over 15 years within the pharmaceutical industry (Organon Biosciences, Schering-Plough and Merck (MSD)), leading drug discovery and development programs in CNS Disorders. Fiona is a graduate of the University of Edinburgh where she gained both BSc and PhD degrees in pharmacology.

Dr Frank Yocca

Dr Yocca is an internationally recognized pharmaceutical R&D executive and scientist. He has wide ranging expertise in leading and working in high performance world-class teams in drug discovery, development and external diligence. At Bristol-Myers Squibb Company he held a variety of discovery leadership positions. Dr Yocca contributed significantly to and became a leader in 5-HT and melatonin receptor research, utilizing scientific discoveries to drive many diverse discovery programs in anxiety, depression, schizophrenia, cognition, sleep disorders and migraine. This work in part contributed to the approval and marketing of four neuropsychiatric agents (Buspar®, Serzone® Abilify® and Heltioz®. Frank was also involved in the clinical development of the antipsychotic Abilify®, as a study director for Phase III Intramuscular Formulation and Phase IV Regulatory Studies. Between 2005 and 2015, Frank held multiple leadership roles at AstraZeneca including Vice President and Site Head, CNS and Pain Discovery Research Wilmington and Vice President, Strategy and Externalization in the Neuroscience Innovative Medicines Unit (iMed). He also contributed to the design and implementation of a new, novel Virtual Neuroscience iMed that focused on outsourcing and in-licensing as the key driver for building portfolio value. He is a recognized scientific leader in the Neuroscience community and member of a number of influential scientific organizations including the Institute of Medicine of the National Academy of Science, and a Fellow of American College of Neuropsychopharmacology.